drugset
drugset / Trial / NCT00255333

INNO-105 in Patients With Solid Tumors

NCT00255333 ↗

Phase 1 Terminated 24 enrolled Innovive Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The safety, tolerability and pharmacokinetics of INNO-105, an investigational anticancer drug, are being studied in patients with solid tumors.

Timeline

Start
2005-11
Primary completion
—
Completion
2007-03

Outcome

Outcome not reported

Stopped: “Development of this compound was discontinued.”

Drugs

EvaluationDrugModalityDoseRoute
Subject metenkefalin Peptide — Intravenous

Indications

neoplasm